T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET
Company Participants
John Sperzel - Chairman and CEO
John Sprague - CFO
Conference Call Participants
Mark Massaro - BTIG
Ben Haynor - Alliance Global Partners
Kyle Mikson - Canaccord Genuity
Operator
Good day everyone and welcome to the T2 Biosystems Inc. Fourth Quarter and Full-Year 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
It is now my pleasure to turn the floor over to your host, [indiscernible] Investor Relations. Ma'am the floor is yours.
Unidentified Company Representative
Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products.
Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements including the risks and uncertainties described in T2 Biosystems' Annual Report on Form 10-K filed with the SEC on March 23, 2022, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
With that, I would like to turn the call over to Chairman and CEO, John Sperzel. John?
John Sperzel
Thank you all for joining our fourth quarter and full-year 2022 earnings call. Today, I will discuss our performance in the fourth quarter, the progress we have made across our three corporate priorities, and our outlook for 2023.
I will then turn the call over to John Sprague, our Chief Financial Officer, who will review our fourth quarter and full-year financial results. Before I provide closing remarks and we open the call for questions and answers, I want to start by recognizing the T2 Biosystems team for achieving a number of sales records and key accomplishments during 2022.
Commercially, we achieved record full-year 2022 Sepsis and related product revenue that is non-COVID product revenue and a record number of full-year Sepsis driven T2Dx instrument contracts. We also ended the year on a high note with record fourth quarter U.S. sepsis test sales.